292 related articles for article (PubMed ID: 13130254)
1. [Effect of preservatives on the conjunctiva: a comparative study of beta-blocker eye drops with and without preservatives in glaucoma patients].
Pisella PJ; Lala E; Parier V; Brignole F; Baudouin C
J Fr Ophtalmol; 2003 Sep; 26(7):675-9. PubMed ID: 13130254
[TBL] [Abstract][Full Text] [Related]
2. [Flow cytometric analysis of HLA-DR, IL-6 and IL-8 expression by conjunctival epithelial cells from patients with prolonged topical antiglaucoma treatments].
Bensoussan L; Blondin C; Baudouin C; Hamard P; Sabeh Afaki G; Creuzot-Garcher C; Warnet JM; Brignole-Baudouin F
J Fr Ophtalmol; 2003 Oct; 26(8):782-9. PubMed ID: 14586218
[TBL] [Abstract][Full Text] [Related]
3. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study.
Pisella PJ; Debbasch C; Hamard P; Creuzot-Garcher C; Rat P; Brignole F; Baudouin C
Invest Ophthalmol Vis Sci; 2004 May; 45(5):1360-8. PubMed ID: 15111589
[TBL] [Abstract][Full Text] [Related]
4. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells.
Guenoun JM; Baudouin C; Rat P; Pauly A; Warnet JM; Brignole-Baudouin F
Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2444-50. PubMed ID: 15980234
[TBL] [Abstract][Full Text] [Related]
5. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies.
Baudouin C; Pisella PJ; Fillacier K; Goldschild M; Becquet F; De Saint Jean M; Béchetoille A
Ophthalmology; 1999 Mar; 106(3):556-63. PubMed ID: 10080214
[TBL] [Abstract][Full Text] [Related]
6. Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term.
Baudouin C; Hamard P; Liang H; Creuzot-Garcher C; Bensoussan L; Brignole F
Ophthalmology; 2004 Dec; 111(12):2186-92. PubMed ID: 15582072
[TBL] [Abstract][Full Text] [Related]
7. Conjunctival markers as predictable markers for preoperative glaucoma assessment.
Pisella PJ
Br J Ophthalmol; 2006 Nov; 90(11):1335-6. PubMed ID: 17057168
[TBL] [Abstract][Full Text] [Related]
8. [Toxicity of preserved and unpreserved beta-blocker eyedrops in an in vitro model of human conjunctival cells].
de Saint Jean M; Debbasch C; Brignole F; Rat P; Warnet JM; Baudouin C
J Fr Ophtalmol; 2000 Feb; 23(2):111-21. PubMed ID: 10705112
[TBL] [Abstract][Full Text] [Related]
9. Trefoil factor family 1, MUC5AC and human leucocyte antigen-DR expression by conjunctival cells in patients with glaucoma treated with chronic drugs: could these markers predict the success of glaucoma surgery?
Souchier M; Buron N; Lafontaine PO; Bron AM; Baudouin C; Creuzot-Garcher C
Br J Ophthalmol; 2006 Nov; 90(11):1366-9. PubMed ID: 16809382
[TBL] [Abstract][Full Text] [Related]
10. [Structural and immunohistochemical changes of conjunctiva induced by topical glaucoma medication].
Nenciu A; Stefan C; Ardelean C
Oftalmologia; 2004; 48(1):35-42. PubMed ID: 15279417
[TBL] [Abstract][Full Text] [Related]
11. Influence of timolol, benzalkonium-preserved timolol, and benzalkonium-preserved brimonidine on oxidative stress biomarkers in the tear film.
Sedlak L; Wojnar W; Zych M; Wyględowska-Promieńska D
Cutan Ocul Toxicol; 2020 Sep; 39(3):260-268. PubMed ID: 32594785
[TBL] [Abstract][Full Text] [Related]
12. A rabbit dry eye model induced by topical medication of a preservative benzalkonium chloride.
Xiong C; Chen D; Liu J; Liu B; Li N; Zhou Y; Liang X; Ma P; Ye C; Ge J; Wang Z
Invest Ophthalmol Vis Sci; 2008 May; 49(5):1850-6. PubMed ID: 18436819
[TBL] [Abstract][Full Text] [Related]
13. Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes.
Brignole F; Pisella PJ; Goldschild M; De Saint Jean M; Goguel A; Baudouin C
Invest Ophthalmol Vis Sci; 2000 May; 41(6):1356-63. PubMed ID: 10798650
[TBL] [Abstract][Full Text] [Related]
14. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways.
Baudouin C; Liang H; Hamard P; Riancho L; Creuzot-Garcher C; Warnet JM; Brignole-Baudouin F
Ophthalmology; 2008 Jan; 115(1):109-15. PubMed ID: 17532048
[TBL] [Abstract][Full Text] [Related]
15. Effects of benzalkonium chloride- and polyquad-preserved combination glaucoma medications on cultured human ocular surface cells.
Ammar DA; Noecker RJ; Kahook MY
Adv Ther; 2011 Jun; 28(6):501-10. PubMed ID: 21603985
[TBL] [Abstract][Full Text] [Related]
16. Adverse effects of topical antiglaucomatous medications on the conjunctiva and the lachrymal (Brit. Engl) response.
Nuzzi R; Finazzo C; Cerruti A
Int Ophthalmol; 1998; 22(1):31-5. PubMed ID: 10090446
[TBL] [Abstract][Full Text] [Related]
17. Polyquad-preserved travoprost/timolol, benzalkonium chloride (BAK)-preserved travoprost/timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface study.
Liang H; Brignole-Baudouin F; Pauly A; Riancho L; Baudouin C
Adv Ther; 2011 Apr; 28(4):311-25. PubMed ID: 21424577
[TBL] [Abstract][Full Text] [Related]
18. [Modification of tear film break-up time by beta blocker eyedrops without preservatives].
Marquardt R; Schubert T
Klin Monbl Augenheilkd; 1991 Aug; 199(2):75-8. PubMed ID: 1960936
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.
Avunduk AM; Tekelioglu Y; Turk A; Akyol N
Clin Ther; 2005 Sep; 27(9):1392-402. PubMed ID: 16291412
[TBL] [Abstract][Full Text] [Related]
20. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology.
Martone G; Frezzotti P; Tosi GM; Traversi C; Mittica V; Malandrini A; Pichierri P; Balestrazzi A; Motolese PA; Motolese I; Motolese E
Am J Ophthalmol; 2009 Apr; 147(4):725-735.e1. PubMed ID: 19181302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
